Business, energy, technology, markets and global industry news from Business News Today

alpha-synuclein

PharmaDeviceNews alpha-synuclein
Medical Devices & Diagnostics

What Spear Bio’s new pTau 217 assay reveals about where Alzheimer’s biomarker detection is heading

Spear Bio debuts BD-pTau 217, alpha-synuclein and pS129-a-syn assays at AD/PD 2026. What the claims mean for Alzheimer's and Parkinson's research. Read the analysis.

Read More
Pharma & Biotech

Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests

Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.

Read More
Pharma & Biotech

Parkinson’s disease research shifts toward proteoform-level resolution with Nautilus Biotechnology’s platform

Find out how proteoform-level proteomics could transform Parkinson’s biomarker research and reshape future clinical trials.

Read More